Discuss the science of human genetics, DNA testing, genomic research, hereditary conditions, and the future of personalized medicine.
Posted by GeneticsCurious · 54 replies
Consumer genetic tests like 23andMe and AncestryDNA analyze hundreds of thousands of single nucleotide polymorphisms (SNPs) across your genome to estimate ancestry composition, identify distant relatives, and screen for certain health-related variants. The health reports cover areas such as carrier status for conditions like cystic fibrosis, predisposition reports for conditions like BRCA1/BRCA2 variants associated with breast cancer risk, and wellness traits like caffeine metabolism. These tests do not sequence your entire genome, so they miss many rare variants that a clinical whole-exome or whole-genome sequencing test would detect. Results should always be interpreted with a genetic counselor for medical decisions.
Posted by BRCAQuestions · 47 replies
BRCA1 and BRCA2 are tumor suppressor genes; pathogenic variants in these genes significantly elevate lifetime risk for breast and ovarian cancers. Women with a BRCA1 pathogenic variant face a lifetime breast cancer risk of approximately 55% to 72%, compared to about 12% in the general population. BRCA2 variants are also associated with elevated risks for prostate and pancreatic cancers in both sexes. Not all variants in these genes are pathogenic — many are classified as variants of uncertain significance, requiring further clinical evaluation before any medical action is taken.
Posted by TestingAccuracy · 39 replies
Direct-to-consumer genetic tests are generally accurate for the specific variants they report, with genotyping accuracy typically above 99% for well-validated SNPs. However, their scope is limited compared to clinical-grade whole-exome or whole-genome sequencing, which can identify millions of additional variants. Consumer tests also use different laboratory standards than CLIA-certified clinical laboratories, meaning results may not be used for clinical decision-making without independent confirmation. The FDA regulates which health reports consumer tests can offer in the United States, restricting the most medically actionable findings to certified settings.
Posted by PolygenicRisk · 33 replies
A polygenic risk score (PRS) aggregates the effects of thousands to millions of common genetic variants to estimate an individual's relative risk for complex traits like type 2 diabetes, coronary artery disease, or schizophrenia. Current PRS models are more predictive than single-gene variants for most common diseases, but they are not deterministic — a high PRS indicates elevated statistical risk, not certainty of disease. PRS accuracy also varies significantly across populations, with most existing models trained predominantly on European-ancestry cohorts, which limits applicability across diverse populations. Research into more inclusive, multi-ancestry PRS models is an active area of genomics in 2026.
Posted by PharmacogenomicsQ · 44 replies
Pharmacogenomics is the study of how genetic variation affects an individual's response to drugs, including both efficacy and risk of adverse reactions. For example, variants in the CYP2C19 gene influence how quickly the body metabolizes clopidogrel (a blood thinner), with poor metabolizers receiving little benefit from standard doses. The FDA has included pharmacogenomic information in the labeling of over 250 drugs across many therapeutic categories. Clinical pharmacogenomic testing, offered through laboratories like Genomind and Myriad Genetics, can help physicians choose medications and dosages that are better suited to a patient's individual genetic profile.
Posted by WGSCost2026 · 38 replies
Whole genome sequencing (WGS) has become dramatically more affordable over the past decade, dropping from approximately $1 million per genome in 2007 to under $200 for raw sequencing in high-throughput research settings as of 2026. Consumer-facing WGS services such as Nebula Genomics offer personal genome sequencing for a few hundred dollars, though clinical interpretation remains a separate cost. Medicare and many insurance plans now cover clinical WGS for specific indications, including rare disease diagnosis in pediatric patients. The cost of expert interpretation and bioinformatic analysis remains a significant portion of the total investment for medically actionable WGS.
Posted by GeneticPrivacy · 42 replies
The Genetic Information Nondiscrimination Act (GINA), enacted in 2008, prohibits health insurers and employers from discriminating based on genetic information. However, GINA does not cover life insurance, disability insurance, or long-term care insurance, leaving important gaps in protection. Consumer genetic testing companies store DNA data under their privacy policies, which vary in scope regarding data sharing with third parties and law enforcement. In 2023 and 2024, several high-profile security breaches at consumer genetics companies highlighted the risks of centralized genetic data storage. Consumers can reduce risk by reviewing data-sharing settings and understanding companies' policies before submitting a sample.
Posted by GenomicsMethods · 29 replies
Genotyping interrogates specific, pre-selected positions in the genome — typically common SNPs known to be informative for ancestry, disease risk, or trait prediction. Arrays used by consumer genetics companies test 500,000 to over 2 million SNP positions simultaneously. Sequencing, by contrast, reads all or selected portions of the DNA nucleotide sequence, capturing both common and rare variants including insertions, deletions, and structural changes that arrays would miss. Whole-genome sequencing reads the approximately 3.2 billion base pairs of the human genome, while whole-exome sequencing targets only the 1-2% that codes for proteins. Sequencing is more comprehensive but more expensive and generates larger amounts of data requiring bioinformatic analysis.
Posted by HereditaryVsSporadic · 36 replies
Hereditary conditions result from pathogenic variants in single genes or chromosomal abnormalities that are transmitted from parent to child following patterns such as autosomal dominant, autosomal recessive, or X-linked inheritance. Examples include Huntington's disease (dominant), cystic fibrosis (recessive), and fragile X syndrome (X-linked). Sporadic conditions arise from de novo mutations, somatic mutations, environmental factors, or complex polygenic interactions that are not inherited from parents. Many cancers are sporadic, caused by acquired somatic mutations in tumor tissue rather than germline variants. Understanding the distinction is critical for determining whether genetic testing of family members is warranted.
Posted by EpigeneticsExplained · 31 replies
Epigenetics refers to heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. Common epigenetic mechanisms include DNA methylation, which typically silences gene expression, and histone modification, which can either activate or repress genes depending on the specific chemical modification. Environmental factors such as diet, stress, and toxin exposure can alter epigenetic patterns, potentially affecting gene expression and health outcomes across an individual's lifetime. Some epigenetic changes can be transmitted to offspring, a phenomenon studied in the field of transgenerational epigenetics. Research into reversible epigenetic modifications has opened new avenues for therapeutic intervention in cancer and other diseases.
Join thousands of members sharing knowledge and experiences.